Microbial expression of Exendin-4 analog and its efficacy in mice model.
Biologicals · 2017
Last updated 2026-05-28Researchers created a version of the GLP-1 drug Exendin-4 using bacteria, then tested it in mice. In a glucose tolerance test, the bacterial version worked as well as the standard drug (Byetta) at lowering blood sugar, with no differences in effectiveness between the two.
AI summary of the abstract below.
| Journal | Biologicals, 2017 |
|---|---|
| Citations | 1 |
| Relative citation ratio | 0.05 |
| NIH percentile | 5 |
| Molecules | — |
| Conditions studied | Type 2 Diabetes, Obesity |
Abstract
Exendin-4 is a GLP 1 agonist incretin-mimetic peptide hormone comprising 39 amino acids. Exenatide (Byetta) is a chemically synthesized version of Exendin-4 with an additional C-terminal amidation. Exenatide acts as a GLP-1 receptor agonist. This paper illustrates the method adopted for cloning, fermentation and purification of recombinant Exendin-4 analog expressed in Escherichia coli. The biologically expressed analog was extensively characterized using different orthogonal methods to confirm their biological activity and physicochemical properties. It was observed that the expressed analog showed comparable functional properties as that of Byetta irrespective of their modes of development. Further, in vivo efficacy of the recombinant Exendin-4 analog was studied in Oral Glucose Tolerance Test (OGTT) in mice models. Byetta and Exendin-4 analog treated groups showed comparable glucose lowering activity in the OGTT model.
Verbatim abstract via PubMed 28554726 ↗